Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Operating activities:
Net (loss) income	$ (126,817)	$ (69,707)	$ 26,144
Adjustments to reconcile net (loss) income to net cash used in operating activities:
Stock-based compensation	6,155	7,353	7,686
Depreciation	425	1,402	1,621
Amortization of debt issuance costs and debt discount	887	991	791
Change in fair value of common stock warrant liabilities	(297)	(5,387)	1,103
Change in fair value of contingent consideration	24,100	1,800	(2,000)
Inventory write-down	2,232	0	0
Asset impairment charges	1,116	8,431	0
Loss on sale of marketable securities	0	0	5,746
Loss on extinguishment of debt	4,876	0	0
Gain on sale of business	0	0	(89,484)
Changes in operating assets and liabilities:
Trade accounts receivable	9,356	(11,181)	7,477
Inventory	2,583	4,983	1,394
Prepaid expenses and other current assets	(801)	(3,394)	(650)
Other assets	(2,784)	471	316
Accounts payable, accrued expenses and other liabilities	4,340	(1,778)	(14,232)
Deferred revenue	(1,245)	(5,839)	(8,464)
Deferred tax liability	0	(1,025)	(2,050)
Net cash used in operating activities	(75,874)	(72,880)	(64,602)
Investing activities:
Purchases of property and equipment	(76)	(103)	(308)
Proceeds from divestiture of businesses	0	0	82,984
Change in restricted cash from divestiture of businesses	0	10,002	(1,502)
Proceeds from sale of marketable securities	0	0	4,371
Net cash (used in) provided by investing activities	(76)	9,899	85,545
Financing activities:
Proceeds from borrowings	0	2,167	0
Principal repayments of long-term debt	(20,000)	(3,334)	(1,450)
Payment of fees to extinguish long-term debt	(1,865)	0	0
Proceeds from issuance of common stock under equity incentive plans	9,176	350	1,441
Proceeds from issuance of common stock, net of offering costs	290,591	0	92,210
Net cash provided by (used in) financing activities	277,902	(817)	92,201
Net increase (decrease) in cash and cash equivalents	201,952	(63,798)	113,144
Cash and cash equivalents at beginning of period	91,551	155,349	42,205
Cash and cash equivalents at end of period	293,503	91,551	155,349
Supplemental disclosure of cash flow information:
Cash paid for interest	1,475	1,470	1,466
Extinguishment of Endo working capital advance note payable through net settlement of balances owed to the Company	$ 7,000	$ 0	$ 0